Status:

COMPLETED

1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses

Lead Sponsor:

Bausch & Lomb Incorporated

Conditions:

Refractive Ametropia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Experienced soft contact lens wearing subjects will be enrolled in this 1-week, post-market, bilateral, repeated measures, dispensing study. All subjects will be seen for a Screening/Dispensing Visit ...

Eligibility Criteria

Inclusion

  • Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have capacity to read, understand and provide written voluntary informed consent.
  • Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
  • Have no active ocular disease or allergic conjunctivitis.
  • Not be using any topical ocular medications.
  • Be willing and able to follow instructions.
  • Have signed a statement of informed consent

Exclusion

  • Participating in a conflicting study in the opinion of the Investigator.
  • Considered by the Investigator to not be a suitable candidate for participation.

Key Trial Info

Start Date :

October 4 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 15 2023

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT06053736

Start Date

October 4 2023

End Date

December 15 2023

Last Update

January 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bausch & Lomb, Incorporated

Rochester, New York, United States, 14609

1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses | DecenTrialz